When the US Senate agreed to put aside 2.8 billion dollars to maintain the US bio-terror defence system recently, it did not just spell good news for American citizens, but also for Bavarian Nordic, the Danish company says in a press release.
"We are very pleased that the U.S. government has committed to maintaining and improving their stockpile of medical countermeasures by reauthorizing $2.8 billion in BioShield funding over the next five years," says Bavarian Nordic President and CEO Anders Hedegaard. "This new law will also speed up medical countermeasure development which will benefit our long-term relationship with the U.S. government on the development and stockpiling of current and future biodefense vaccines."
Mere fra MedWatch
Biotekselskabet Evaxion Biotech, der arbejder med udviklingen af vacciner og immunterapi baseret på kunstig intelligens, har sikret sig muligheden for at rejse 100 mio. dollar til finansieringen af selskabets drift i tider med uro på de finansielle markeder. Rettidig omhu, lyder det fra den adm. direktør.